To support tenants using AI, life sciences buildings need increased slab loads, electricity and water, all expensive upgrades for owners.

As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...

An investor whose portfolio contains some value- or income-focused investments and some growth-oriented investments, who ...

On December 17, 2025, IO Biotech, Inc. received a notice from Nasdaq that its common stock no longer met the Nasdaq Global Select Market’s minimum bid price requirement, as its closing bid price had ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...

E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

Explore the potential of CKD drug ISM4808 and its role in treating chronic kidney disease through innovative research.